Overactive pathway activity points to metastatic prostate cancer
Measuring the level of activity of a signaling pathway called Hedgehog may differentiate between localized and metastatic prostate cancer, according to research from Johns Hopkins Medical Institute.
Measuring the level of activity of a signaling pathway called Hedgehog may differentiate between localized and metastatic prostate cancer, according to research from Johns Hopkins Medical Institute.
In the Sept. 12 advance online edition of the journal Nature, Johns Hopkins researchers report that only three of 12 localized prostate cancers obtained at surgery had detectable activity in the Hedgehog signaling pathway. By contrast, all 15 samples of metastatic cancer samples they acquired had detectible Hedgehog pathway activity. Hedgehog pathway activity was also 10 to 100 times higher in the metastatic samples than in the localized cancer samples, the study found.
"If we can use Hedgehog activity to predict whether a tumor will metastasize, we will have a great diagnostic tool, but manipulating the Hedgehog signaling pathway may also offer a completely new way to treat metastatic prostate cancer," said David Berman, MD, PhD, of Johns Hopkins.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
